Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Negative Sentiment
Mechanism of action for investigational menin inhibitors, including ziftomenib
Key Takeaway: The article appears to be incomplete and does not provide relevant information about the mechanism of action for investigational menin inhibitors, including ziftomenib. It primarily consists of a verification prompt and does not delve into the subject matter as expected.
Price reaction · baseline $10.295 (2023-08-08T16:11:00.000Z) · hit during market hours · 1 other KURA headline(s) in the window, move may be shared
day 0 close · peak
+1%
Market Sentiment Analysis
CONCERNS & RISKS
- The article does not provide any substantial information on the mechanism of action.
- There is a lack of detailed insights regarding investigational menin inhibitors.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic